Compound alpha-keto acid dispersible tablet

Abstract

The invention discloses a compound alpha-keto acid dispersible tablet for treating chronic kidney diseases, containing four kinds of keto amino acid calcium, one kind of hydroxyamino acid calcium, five kinds of amino acid and pharmaceutically acceptable adjuvants. The tablet is mainly and clinically used for postponing renal failure process, correcting metabolic disturbance, coordinating with low-protein diet and preventing and treating damages caused by protein metabolism disorder because of chronic renal insufficiency.

Description

A kind of compound α-keto acid dispersible tablet Technical field The invention belongs to the technical field of medicine, and in particular relates to a compound α-ketoacid dispersible tablet and a preparation method thereof. Background technique In recent years, the prevalence of chronic kidney disease has been increasing significantly around the world. In the United States alone, there are currently as many as 20 million people at risk of suffering from this disease. Although there is no exact epidemiological data in China, it is estimated from a single-sample study in Shanghai that there are about 18 million people with the disease. The high incidence of chronic kidney disease is closely related to the improvement of social industrialization, population aging, and the increase of the incidence of diseases that cause kidney damage, especially diabetes. A large part of chronic kidney disease eventually develops into end-stage uremia. Once it enters uremia, renal replac...

AI Technical Summary

Problems solved by technology

A large part of chronic kidney disease eventually develops into end-stage uremia. Once it enters uremia, renal replacement therapy can only be used to maintain life, which will inevitably cause huge mental pressure and economic burden to patients, families and society

Images